Nolvadex Patient Leaflets Should Carry Absolute Benefit/Risk Data - HRG
Executive Summary
Nolvadex medication guides for reduction of breast cancer risk should present absolute risk and benefit data together for the tamoxifen product, Public Citizen's Health Research Group and the National Women's Health Network proposed in a May 4 petition to FDA.